Survival Data Support Tarceva Pricing Premium Over Iressa – Genentech/OSI
This article was originally published in The Pink Sheet Daily
Executive Summary
The Tarceva 25% price premium over AstraZeneca's Iressa is justified based upon survival data, Genentech and OSI said during conference calls announcing the oncologic's approval
You may also be interested in...
Genentech/OSI's Tarceva Will Be Detailed Alongside Herceptin
Tarceva approval comes just three-and-a-half months after application is completed and more than two months ahead of review deadline. Genentech and OSI will begin detailing the non-small cell lung cancer product immediately.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.